Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy

被引：9

作者：

Jacobs, Kenneth ^{[1
]}

Viero, Cedric ^{[2
]}

Godwin, John ^{[3
]}

Baughman, Jan ^{[4
]}

Sun, Jichao ^{[1
]}

Ying, Kang ^{[1
]}

Muth, John ^{[1
]}

Hong, Shengyan ^{[1
]}

Vey, Norbert ^{[5
]}

Sweet, Kendra L. ^{[6
]}

Uy, Geoffrey L. ^{[7
]}

Ravandi, Farhad ^{[8
]}

Foster, Matthew C. ^{[9
]}

Rizzieri, David A. ^{[10
]}

Arellano, Martha L. ^{[11
]}

Rettig, Michael P. ^{[12
]}

Topp, Max S. ^{[13
]}

Huls, Gerwin ^{[14
]}

Lelievre, Helene ^{[2
]}

Paolini, Stefania ^{[15
]}

Ciceri, Fabio ^{[16
]}

Carrabba, Matteo Giovanni ^{[17
]}

Lowenberg, Bob ^{[18
]}

DiPersio, John F. ^{[12
]}

Wigginton, Jon ^{[1
]}

Davidson-Moncada, Jan K. ^{[19
]}

机构：

[1] MacroGenics Inc, Rockville, MD USA

[2] Servier, Paris, France

[3] Providence Portland Med Ctr, Portland, OR USA

[4] MacroGenics Inc, San Francisco, CA USA

[5] Inst Paoli Calmettes, Dept Hematol, Marseille, France

[6] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL USA

[7] Washington Univ, Sch Med, St Louis, MO USA

[8] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[9] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[10] Duke Univ, Med Ctr, Dept Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC 27710 USA

[11] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[12] Washington Univ, Sch Med, Dept Internal Med, Div Oncol, St Louis, MO 63110 USA

[13] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[14] Univ Med Ctr Groningen, Hematol, Groningen, Netherlands

[15] Univ Bologna, Inst Hematol L&A Seragnoli, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[16] Ist Sci San Raffaele, Hematol & Bone Marrow Transplantat Unit, Milan, Italy

[17] IRCCS San Raffaele Sci Inst, Hematol & Bone Marrow Transplantat Unit, Milan, Italy

[18] Erasmus Univ, Med Ctr, Dept Hematol, Rotterdam, Netherlands

[19] MacroGenics Inc, Washington, DC USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-112615

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2738

引用

页数：4

共 50 条

[1] Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy
Bakkacha, Ouiam
Uy, Geoffrey L.
Aldoss, Ibrahim
Foster, Matthew C.
Sallman, David A.
Sweet, Kendra L.
Rizzieri, David A.
Sayre, Peter H.
Advani, Anjali S.
Emadi, Ashkan
Wieduwilt, Matthew J.
Vey, Norbert
Ciceri, Fabio
Carrabba, Matteo Giovanni
Moyo, Tamara
Arellano, Martha L.
Godwin, John E.
Lowenberg, Bob
Huls, Gerwin
Ravandi, Farhad
Tran, Kathy
Muth, John
Baughman, Jan
Jongen-Lavrencic, Mojca
Timmeny, Erin
Topp, Max S.
Paolini, Stefania
Guo, Kuo
Curtis, Teia
Zhao, Jian
Wigginton, Jon
Bonvini, Ezio
Walter, Roland B.
Davidson, Jan
DiPersio, John F.
Jacobs, Kenneth
BLOOD, 2019, 134
[2] Lead-in Dose Optimization to Mitigate Cytokine Release Syndrome in AML and MDS Patients Treated with Flotetuzumab, a CD123 x CD3 Dart® Molecule for T-Cell Redirected Therapy
Jacobs, Kenneth
Godwin, John
Foster, Matthew
Vey, Norbert
Uy, Geoffrey L.
Rizzieri, David A.
Arellano, Martha L.
Rettig, Michael P.
Christ, Stephanie
Topp, Max S.
Huls, Geert
Lowenberg, Bob
Martinelli, Giovanni
Paolini, Stefania
Ciceri, Fabio
Carrabba, Matteo Giovanni
Sun, Jichao
Li, Daner
Tran, Kathy
Spohn, Karen
Baughman, Jan
Shankar, Sadhna
Lelievre, Helene
Bonvini, Ezio
DiPersio, John F.
Wigginton, Jon
Davidson-Moncada, Jan K.
BLOOD, 2017, 130
[3] Interim results from a phase 1 first-in-human study of flotetuzumab, a CD123 x CD3 bispecific DART molecule, in AML/MDS
Vey, N.
Davidson-Moncada, J.
Uy, G. L.
Foster, M.
Rizzieri, D.
Godwin, J.
Topp, M.
Ciceri, F.
Carrabba, M.
Martinelli, G.
Huls, G. A.
Wegener, A.
Shannon, M.
Tran, K.
Sun, J.
Bonvini, E.
Lowenberg, B.
Wigginton, J.
Dipersio, J. F.
ANNALS OF ONCOLOGY, 2017, 28
[4] Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
Uy, Geoffrey L.
Aldoss, Ibrahim
Foster, Matthew C.
Sallman, David A.
Sweet, Kendra L.
Rizzieri, David A.
Sayre, Peter H.
Advani, Anjali S.
Emadi, Ashkan
Wieduwilt, Matthew J.
Vey, Norbert
Ciceri, Fabio
Carrabba, Matteo Giovanni
Moyo, Tamara
Church, Sarah E.
Rettig, Michael P.
Arellano, Martha L.
Godwin, John E.
Lowenberg, Bob
Huls, Gerwin
Ravandi, Farhad
Muth, John
Tran, Kathy
Jongen-Lavrencic, Mojca
Timmeny, Erin
Topp, Max S.
Paolini, Stefania
Guo, Kuo
Curtis, Teia
Zhao, Jian
Vadakekolathu, Jayakumar
Wigginton, Jon M.
Bonvini, Ezio
Rutella, Sergio
Walter, Roland B.
Davidson-Moncada, Jan K.
DiPersio, John F.
BLOOD, 2019, 134
[5] Bone Marrow T Cell Changes By Multiplex IHC after Treatment with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in a Primary Refractory t-AML Patient
Godwin, John
Ballesteros-Merino, Carmen
Bifulco, Carlo B.
Lelievre, Helene
Wigginton, Jon
Davidson-Moncada, Jan K.
Fox, Bernard
BLOOD, 2018, 132
[6] Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 X CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Rutella, Sergio
Church, Sarah E.
Vadakekolathu, Jayakumar
Viboch, Elena
Sullivan, Amy H.
Hood, Tressa
Warren, Sarah E.
Cesano, Alessandra
La Motte-Mohs, Ross
Muth, John
Lelievre, Helene
Lowenberg, Bob
DiPersio, John F.
Davidson-Moncada, Jan K.
BLOOD, 2018, 132
[7] Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+T Cells and CD123+AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients
Godwin, John E.
Ballesteros-Merino, Carmen
Lonberg, Nikhil
Jensen, Shawn
Moudgil, Tarsem
Bifulco, Carlo B.
Wigginton, Jon
Muth, John
Davidson-Moncada, Jan K.
Fox, Bernard
BLOOD, 2019, 134
[8] Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Uy, Geoffrey L.
Godwin, John
Rettig, Michael P.
Vey, Norbert
Foster, Matthew
Arellano, Martha L.
Rizzieri, David A.
Topp, Max S.
Huls, Gerwin
Lowenberg, Bob
Martinelli, Giovanni
Paolini, Stefania
Ciceri, Fabio
Carrabba, Matteo Giovanni
Ballesteros-Merino, Carmen
Bifulco, Carlo B.
Lelievre, Helene
La Motte-Mohs, Ross
Li, Daner
Sun, Jichao
Jacobs, Kenneth
Spohn, Karen
Lonsdale, Nadia
Tran, Kathy
Baughman, Jan
Shannon, Michele
Fox, Bernard
Bonvini, Ezio
Wigginton, Jon
Davidson-Moncada, Jan
DiPersio, John F.
BLOOD, 2017, 130
[9] Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells
Bhagwat, Anand S.
Torres, Leonel
Shestova, Olga
Shestov, Maksim
Frey, Noelle V.
Hexner, Elizabeth O.
Luger, Selina M.
Loren, Alison W.
Martin, Mary Ellen
McCurdy, Shannon R.
Perl, Alexander
Stadtmauer, Edward A.
Mangan, James K.
Brogdon, Jennifer
Fraietta, Joseph A.
Hwang, Wei-Ting
Siegel, Don L.
Kenderian, Saad S.
Porter, David L.
June, Carl
Gill, Saar
BLOOD, 2023, 142
[10] APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR® molecule for redirected T-cell cytotoxicity, induces potent T-cell activation, proliferation and cytotoxicity with limited cytokine release
Comeau, Michael R.
Miller, Robert E.
Bader, Robert
Gottschalk, Rebecca
Daugherty, Mollie
Sewell, Toddy
Misher, Lynda
Parr, Lara
DeFrancesco, Melissa
Bienvenue, David
McMahan, Catherine J.
Hoyos, Gabriela H.
Gross, Jane A.
CANCER RESEARCH, 2018, 78 (13)

← 1 2 3 4 5 →